Search Results

Indapta Therapeutics, Inc. announced that CEO Mark Frohlich, MD, will be giving a plenary talk today titled, “g-NK cells for the treatment of cancer and autoimmune disease” at the New York Academy of Sciences Frontiers in Cancer Immunotherapy Conference.

Kyverna Therapeutics, Inc. (Kyverna) announced today the publication in Proceedings of the National Academy of Sciences (PNAS)1 of a report describing the first use of KYV-101, a fully human anti-CD19 chimeric antigen receptor (CAR) T-cell product candidate, in a 69-year-old patient suffering from treatment-refractory stiff-person syndrome (SPS) as part of a named-patient use in Germany for critically ill individuals who fail conventional therapies.

The Pontifical Academy of Sciences is proud to announce that Dr. Christina Rahm will be honored at its prestigious summit on May 29, 2024, at the Vatican. A distinguished scientist, entrepreneur, and philanthropist, Dr. Rahm has been recognized for her significant contributions to healthcare innovation and her unwavering commitment to improving global health.

Astria Therapeutics, Inc. today announced that it will present two posters at the upcoming European Academy of Allergy and Clinical Immunology (EAACI) Congress in Valencia, Spain on June 1, 2024.

Inteleos, a global non-profit healthcare certification organization, announced that its Point-of-Care Ultrasound Certification Academy launched its comprehensive Maternal Fetal Health Certification, with its new Obstetrics 2nd/3rd Trimester Clinical Certificate.

NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) (“NeuroSense”) announces the presentation of data from the Company’s PARADIGM Phase 2b study of PrimeC during an Emerging Science session (equivalent to Late Breaker) at the American Academy of Neurology Annual Meeting, which validates the previously announced topline data.

The five-year investment will go toward the construction of a new R&D facility in Beijing to develop innovative therapies and integrate the world’s second most populated country into the company’s global strategy.

Eli Lilly will provide the funding and expertise to advance Laekna’s LAE102, a first-in-class monoclonal antibody targeting the activin type IIA receptor to induce weight loss and boost muscle mass.

Tiziana Life Sciences, Ltd. today announces a platform presentation titled, “Treatment of PIRA with Nasal Foralumab Dampens Microglial Activation and Stabilizes Clinical Progression in Non-Active Secondary Progressive MS” at the Annual Meeting of the American Academy of Neurology in Denver, Colorado.